10.1016/j.cmet.2023.11.009 85 XuR.LiuB.ZhouX
An early cohort study on a small number of patients with diabetes ( N = 138) saw reduced depression scores at 18 months in people exposed to exenatide compared with insulin independently from BMI changes 190
Standard qualification criteria include: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related health condition (high blood pressure, type 2 diabetes, high cholesterol) No history of certain medical conditions (medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2) Not pregnant or breastfeeding Top 8 GLP-1 Telehealth Providers Compared 1
Mostly, glucagon-like-peptide-1 medications are prescribed to people who have: A BMI of 30 or more
Instead, they should view GLP1 obesity treatment as a multifaceted intervention that can address both simultaneously where appropriate
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity
